Meryx, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2013-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.meryxpharma.com
Clinical Trials
2
Active:1
Completed:0
Trial Phases
1 Phases
Phase 1:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (100.0%)Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults with Relapsed/Refractory AML, ALL, or MPAL
Phase 1
Recruiting
- Conditions
- Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaMixed Phenotype Acute Leukemia
- Interventions
- First Posted Date
- 2021-05-04
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Meryx, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT04872478
- Locations
- 🇺🇸
Emory University - WINSHIP Cancer Center, Atlanta, Georgia, United States
🇺🇸Emory University, Children's Healthcare of Atlanta, Atlanta, Georgia, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
Pharmacokinetic and Safety Study of MRX-2843 in Adults with Relapsed/Refractory Advanced And/or Metastatic Solid Tumors
Phase 1
Active, not recruiting
- Conditions
- Advanced CancerMetastatic CancerNeoplasmsNeoplastic ProcessesNeoplasm MetastasisPathologic Processes
- Interventions
- First Posted Date
- 2018-04-27
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Meryx, Inc.
- Target Recruit Count
- 42
- Registration Number
- NCT03510104
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
News
No news found